SY-1365 is primarily investigated for its potential in cancer therapy, particularly targeting CDK7, a cyclin-dependent kinase involved in cell cycle regulation and transcription. Its application focuses on disrupting the growth of cancer cells by inhibiting CDK7, which plays a critical role in controlling cell division and gene expression. This makes it a promising candidate for treating various cancers, including ovarian, breast, and hematologic malignancies. Research is ongoing to evaluate its efficacy and safety in clinical trials, with the aim of developing it as a targeted therapy for patients with limited treatment options.